Literature DB >> 16226364

Influence of chronic treatment with olanzapine, clozapine and scopolamine on performance of a learned 8-arm radial maze task in rats.

Antonio Ortega-Alvaro1, Juan Gibert-Rahola, Juan A Micó.   

Abstract

Cognitive deficit is a significant symptom in schizophrenic patients. Use of atypical antipsychotics has been demonstrated to improve some cognitive functions in schizophrenics, as well as in patients with dementia. However, side effects like sedation and muscarinic antagonism induced by these drugs have detracted from this improvement. We are interested in determining the behavioural effect of acute and chronic treatments with olanzapine and clozapine, two atypical antipsychotics, in a paradigm of working memory, and the influence on behavioural response of possible motor effects during test performance. Unspecific muscarinic antagonist scopolamine has been used for comparison. Male Wistar rats were trained on the 8-arm radial maze up to an accuracy level in choice of 80%. Distance travelled in the maze was also measured during test performance. Acute olanzapine, clozapine and scopolamine caused significant impairment of correct performance. Rats treated with olanzapine and clozapine presented a decrease in motor activity level at the same time. After the test at acute dosage, rats were chronically treated for 14 days with olanzapine, clozapine or scopolamine and 24 h after the last dose were again tested in the 8-arm radial maze. Under this procedure, chronic treatment with olanzapine, clozapine and scopolamine did not impair correct task performance and did not modify distance travelled. We concluded that the sedative effect masked a possible effect on working memory after acute administration of olanzapine and clozapine, whereas chronic treatment with olanzapine, clozapine and scopolamine did not adversely affect working memory performance. In the case of scopolamine, it suggests that chronic muscarinic antagonism does not induce memory impairment and for atypical antipsychotics, it suggests that chronic treatment induced a tolerance to acute motor effects of these drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226364     DOI: 10.1016/j.pnpbp.2005.08.020

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  10 in total

Review 1.  Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients.

Authors:  Richard J Beninger; Tyson W Baker; Matthew M Florczynski; Tomek J Banasikowski
Journal:  Neurotox Res       Date:  2010-04-08       Impact factor: 3.911

2.  Allosteric modulation of related ligand-gated ion channels synergistically induces long-term potentiation in the hippocampus and enhances cognition.

Authors:  Timothy B Johnstone; Zhenglin Gu; Ryan F Yoshimura; Anne-Sophie Villegier; Derk J Hogenkamp; Edward R Whittemore; Jin-Cheng Huang; Minhtam B Tran; James D Belluzzi; Jerrel L Yakel; Kelvin W Gee
Journal:  J Pharmacol Exp Ther       Date:  2010-12-15       Impact factor: 4.030

3.  Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators.

Authors:  Herman J Ng; Edward R Whittemore; Minhtam B Tran; Derk J Hogenkamp; Ron S Broide; Timothy B Johnstone; Lijun Zheng; Karen E Stevens; Kelvin W Gee
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

4.  Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.

Authors:  Rita Citraro; Antonio Leo; Rossana Aiello; Michela Pugliese; Emilio Russo; Giovambattista De Sarro
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

5.  Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment.

Authors:  Y Chertkow; O Weinreb; M B H Youdim; H Silver
Journal:  J Neural Transm (Vienna)       Date:  2007-06-18       Impact factor: 3.575

6.  Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine.

Authors:  Nima Davoodi; Mikhail Kalinichev; Sergei A Korneev; Peter G Clifton
Journal:  Psychopharmacology (Berl)       Date:  2008-12-04       Impact factor: 4.530

7.  Cognitive performance in neurokinin 3 receptor knockout mice.

Authors:  R E Nordquist; M Delenclos; T M Ballard; H Savignac; M Pauly-Evers; L Ozmen; W Spooren
Journal:  Psychopharmacology (Berl)       Date:  2008-03-20       Impact factor: 4.530

8.  Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats.

Authors:  Montserrat Victoriano; Dominique Hermier; Patrick C Even; Gilles Fromentin; Jean-François Huneau; Daniel Tomé; Renaud de Beaurepaire
Journal:  Psychopharmacology (Berl)       Date:  2009-07-02       Impact factor: 4.530

Review 9.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

Review 10.  Drugs Interfering with Muscarinic Acetylcholine Receptors and Their Effects on Place Navigation.

Authors:  Jan Svoboda; Anna Popelikova; Ales Stuchlik
Journal:  Front Psychiatry       Date:  2017-11-09       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.